Company: Amgen Inc.
Job title: Principal Scientist
Adrian Ortiz received his B.S. in chemistry from the University of Arizona in 2004 where he performed research under the guidance of Professor Dominic V. McGrath. He then joined the group of Professor K.C. Nicolaou at the Scripps Research Institute in San Diego, CA where he studied the total synthesis of natural products. After completion of his Ph.D. in 2009, he joined the process group of Bristol-Myers Squibb and in 2019 he joined Amgen in Thousand Oaks, CA where he is currently Head of Pre-Pivotal Drug Substance Technologies and Biocatalysis.
Panel: Biocatalysis for a Sustainable Pharma Future 9:00 am
• Improving the productivity and the quality of APIs and intermediates, whilst also achieving cost savings and greater sustainability. • What evidence is there that biocatalysis is advantageous over traditional catalytic manufacturing methodsRead more
day: Day Two